Plot No.367, Abhey Pur, Industrial Area Phase-1, Panchkula, Haryana 134109
Don't miss out on this limited-time offer to join our successful PCD Pharma network. Fill in your details below and our team will get in touch with you to discuss the best franchise opportunities tailored to your needs.
Deferasirox (180mg) Tablet
Therapeutic Category
Nephrology
Dosage Form
Tablet
Packaging Type
Alu Alu
Packaging
10*10
Price
₹1/-
High-resolution images and Product visuals
Product overview and usage information
Detailed information and research documents
Deferise 180 Tablet containing Deferasirox 180 mg is a targeted iron chelation therapy formulated for patients who require regular blood transfusions. It helps in reducing excess iron, protecting organs, and maintaining overall health in chronic hematological conditions.
Deferasirox works by binding to excess iron in the bloodstream and facilitating its removal through urine and feces. This helps maintain safe iron levels and prevents complications such as liver and heart damage.
The oral tablet provides a convenient, non-invasive option for iron chelation, ensuring better patient compliance and consistent control of iron levels. Its effectiveness makes it suitable for long-term management of iron overload.
With increasing awareness of iron management and demand for chronic care therapies, this formulation offers excellent market potential. Its reliable clinical performance, steady prescription support, and growing adoption make it a valuable addition for expanding business in the hematology segment.
Some patients may experience nausea, vomiting, diarrhea, abdominal discomfort, or skin rash. Rarely, serious effects such as liver or kidney dysfunction, auditory or visual disturbances, or severe allergic reactions may occur and require immediate medical attention.
Deferise 180 Tablet containing Deferasirox 180 mg is a targeted iron chelation therapy formulated for patients who require regular blood transfusions. It helps in reducing excess iron, protecting organs, and maintaining overall health in chronic hematological conditions. Deferasirox works by binding to excess iron in the bloodstream and facilitating its removal through urine and feces. This helps maintain safe iron levels and prevents complications such as liver and heart damage. The oral tablet provides a convenient, non-invasive option for iron chelation, ensuring better patient compliance and consistent control of iron levels. Its effectiveness makes it suitable for long-term management of iron overload. With increasing awareness of iron management and demand for chronic care therapies, this formulation offers excellent market potential. Its reliable clinical performance, steady prescription support, and growing adoption make it a valuable addition for expanding business in the hematology segment.
This medicine should be used strictly under medical supervision. Patients with pre-existing liver or kidney disorders should consult their healthcare provider before use. Regular monitoring of iron levels, liver, and kidney function is recommended during therapy to ensure safe and effective treatment.
Store in a cool, dry place below 25°C, protected from moisture and direct sunlight. Keep the tablets in their original packaging and out of reach of children.
Composition : Atracurium (10mg) Injection
Composition : Thiocolchicoside (4mg) Capsule
Composition : Thiocolchicoside (4mg) Injection
Composition : Aceclofenac (100mg) + Paracetamol (325mg) + Chlorzoxazone (250mg) Tablet
Composition : Drotaverine (80mg) + Aceclofenac (100mg) Tablet
Composition : Aceclofenac (100mg) + Thiocolchicoside (4mg) Tablet
Composition : Aceclofenac (100mg) + Thiocolchicoside (8mg) Tablet
Composition : Baclofen (10mg) Tablet
Composition : Baclofen (20mg) Tablet
This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.
Deferasirox 180mg Tablet has strong demand in the hematology and chronic care segment, making it a high-value product for medical distributors, wholesalers, and pharma franchise partners looking to expand in the PCD pharma pharma franchise market.
Medical distributors and wholesalers can benefit from consistent demand in iron overload management, especially in patients undergoing repeated blood transfusions such as thalassemia and chronic anemia cases. It strengthens their hematology and specialty care portfolio.
Yes, Cafoli Lifecare offers PCD pharma pharma franchise opportunities for Deferasirox 180mg Tablet with monopoly rights, quality packaging, competitive pricing, and reliable supply support for distributors and medical agencies.
Wholesalers and medical agencies benefit from steady chronic therapy demand, institutional prescriptions, and strong specialty-care market opportunities when partnering with Cafoli Lifecare.
Medical distributors, stockists, wholesalers, and pharma professionals interested in this hematology formulation can contact Cafoli Lifecare to discuss PCD pharma franchise opportunities, bulk procurement, pricing details, and distribution support services.